Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 61 | 9.930 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 104 | 8.950 |
Why?
|
| Portal Vein | 30 | 2022 | 45 | 7.940 |
Why?
|
| Liver | 21 | 2022 | 135 | 6.290 |
Why?
|
| Liver Regeneration | 17 | 2022 | 24 | 4.580 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 107 | 3.150 |
Why?
|
| Ligation | 22 | 2022 | 36 | 2.290 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 53 | 2.100 |
Why?
|
| Laparoscopy | 6 | 2021 | 185 | 1.530 |
Why?
|
| Postoperative Complications | 13 | 2022 | 827 | 1.230 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 3 | 1.200 |
Why?
|
| Liver Diseases | 2 | 2018 | 33 | 1.040 |
Why?
|
| Humans | 56 | 2024 | 23495 | 0.980 |
Why?
|
| Cause of Death | 3 | 2017 | 56 | 0.980 |
Why?
|
| Registries | 9 | 2019 | 180 | 0.960 |
Why?
|
| Liver Failure | 4 | 2019 | 10 | 0.870 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3058 | 0.850 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 25 | 0.830 |
Why?
|
| Hypoxia | 2 | 2020 | 33 | 0.740 |
Why?
|
| Hypertrophy | 5 | 2022 | 22 | 0.740 |
Why?
|
| Male | 36 | 2021 | 12823 | 0.730 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3082 | 0.700 |
Why?
|
| Organ Size | 9 | 2019 | 87 | 0.700 |
Why?
|
| Sarcopenia | 1 | 2021 | 25 | 0.670 |
Why?
|
| Middle Aged | 26 | 2019 | 8096 | 0.630 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 35 | 0.620 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 70 | 0.610 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 112 | 0.610 |
Why?
|
| Female | 31 | 2021 | 13305 | 0.600 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 236 | 0.580 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 11 | 0.580 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 50 | 0.570 |
Why?
|
| Hepatomegaly | 1 | 2018 | 7 | 0.570 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 3 | 0.570 |
Why?
|
| Publication Bias | 1 | 2018 | 4 | 0.560 |
Why?
|
| Antioxidants | 1 | 2018 | 56 | 0.550 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 104 | 0.550 |
Why?
|
| Oxidative Stress | 1 | 2018 | 87 | 0.550 |
Why?
|
| Bibliometrics | 1 | 2018 | 24 | 0.540 |
Why?
|
| Aged | 20 | 2019 | 7709 | 0.530 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 23 | 0.520 |
Why?
|
| Length of Stay | 5 | 2021 | 298 | 0.500 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 88 | 0.480 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 5 | 0.480 |
Why?
|
| Animals | 8 | 2021 | 3321 | 0.470 |
Why?
|
| Catheter Ablation | 1 | 2015 | 37 | 0.430 |
Why?
|
| Graft Rejection | 4 | 2008 | 63 | 0.420 |
Why?
|
| Liver Transplantation | 3 | 2015 | 81 | 0.410 |
Why?
|
| Risk Factors | 10 | 2019 | 2026 | 0.400 |
Why?
|
| Time Factors | 9 | 2019 | 1276 | 0.400 |
Why?
|
| Prognosis | 8 | 2020 | 737 | 0.390 |
Why?
|
| Hepatic Veins | 4 | 2022 | 10 | 0.390 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 53 | 0.380 |
Why?
|
| Feasibility Studies | 4 | 2016 | 210 | 0.350 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1492 | 0.340 |
Why?
|
| Survival Rate | 6 | 2018 | 320 | 0.330 |
Why?
|
| Operative Time | 4 | 2019 | 81 | 0.330 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 135 | 0.310 |
Why?
|
| Tissue Donors | 2 | 2021 | 67 | 0.310 |
Why?
|
| Models, Animal | 3 | 2020 | 103 | 0.310 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 353 | 0.300 |
Why?
|
| Random Allocation | 3 | 2018 | 103 | 0.300 |
Why?
|
| Isoantibodies | 2 | 2006 | 7 | 0.290 |
Why?
|
| Adult | 15 | 2019 | 7090 | 0.290 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 12 | 0.280 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 32 | 0.280 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 11 | 0.280 |
Why?
|
| Swine | 2 | 2018 | 68 | 0.270 |
Why?
|
| Death | 1 | 2008 | 40 | 0.270 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 17 | 0.270 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 23 | 0.260 |
Why?
|
| Patient Selection | 4 | 2018 | 171 | 0.260 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 115 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 164 | 0.260 |
Why?
|
| Rats, Wistar | 2 | 2017 | 54 | 0.250 |
Why?
|
| Rats | 2 | 2020 | 625 | 0.250 |
Why?
|
| Risk Assessment | 5 | 2019 | 552 | 0.250 |
Why?
|
| Switzerland | 3 | 2021 | 8 | 0.240 |
Why?
|
| Plasmapheresis | 1 | 2006 | 12 | 0.240 |
Why?
|
| HLA Antigens | 1 | 2006 | 12 | 0.240 |
Why?
|
| Antibody Formation | 1 | 2006 | 14 | 0.230 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 3 | 0.220 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 6 | 0.210 |
Why?
|
| Spirituality | 1 | 2004 | 78 | 0.200 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 807 | 0.190 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 31 | 0.190 |
Why?
|
| Ultrasonography | 3 | 2021 | 207 | 0.180 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 297 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2020 | 165 | 0.180 |
Why?
|
| Biomarkers | 3 | 2020 | 486 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2019 | 313 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 12 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2021 | 32 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 197 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 23 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 53 | 0.170 |
Why?
|
| Hospitals | 1 | 2021 | 157 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 111 | 0.160 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 1 | 0.160 |
Why?
|
| Adrenalectomy | 1 | 2019 | 5 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 54 | 0.150 |
Why?
|
| Brazil | 2 | 2016 | 35 | 0.150 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 14 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 15 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 80 | 0.150 |
Why?
|
| Hospital Mortality | 3 | 2015 | 130 | 0.150 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 2 | 0.150 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 3 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2019 | 68 | 0.150 |
Why?
|
| Liver Function Tests | 4 | 2017 | 21 | 0.140 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 16 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 594 | 0.140 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 4 | 0.140 |
Why?
|
| Paracrine Communication | 1 | 2018 | 3 | 0.140 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 11 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 17 | 0.140 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 18 | 0.140 |
Why?
|
| Cytoprotection | 1 | 2018 | 9 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 18 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2018 | 10 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 23 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 31 | 0.140 |
Why?
|
| Anesthesia | 1 | 2018 | 28 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 42 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 32 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 39 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 55 | 0.140 |
Why?
|
| Models, Biological | 1 | 2020 | 303 | 0.140 |
Why?
|
| Logistic Models | 3 | 2016 | 357 | 0.140 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 246 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2017 | 227 | 0.130 |
Why?
|
| Gastric Bypass | 1 | 2018 | 68 | 0.130 |
Why?
|
| Portal Pressure | 1 | 2017 | 4 | 0.130 |
Why?
|
| Liver Circulation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Apoptosis | 1 | 2018 | 201 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 250 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 608 | 0.130 |
Why?
|
| Melanoma | 1 | 2017 | 49 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2017 | 26 | 0.130 |
Why?
|
| Hyperplasia | 1 | 2017 | 19 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 8 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2017 | 1500 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2018 | 392 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 3 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 162 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 4 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 533 | 0.120 |
Why?
|
| Obesity | 1 | 2018 | 288 | 0.120 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 2 | 0.110 |
Why?
|
| Methyl Ethers | 1 | 2015 | 6 | 0.110 |
Why?
|
| Propofol | 1 | 2015 | 9 | 0.110 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 9 | 0.110 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 12 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 38 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 99 | 0.110 |
Why?
|
| Surgeons | 1 | 2016 | 79 | 0.110 |
Why?
|
| Safety | 1 | 2014 | 35 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 88 | 0.100 |
Why?
|
| Viscera | 1 | 2013 | 2 | 0.100 |
Why?
|
| Renal Artery | 1 | 2013 | 6 | 0.100 |
Why?
|
| Vascular Patency | 1 | 2013 | 17 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 13 | 0.100 |
Why?
|
| Aneurysm | 1 | 2013 | 10 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 27 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 75 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2012 | 59 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 203 | 0.090 |
Why?
|
| Bilirubin | 2 | 2016 | 10 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Health Care Rationing | 1 | 2011 | 6 | 0.090 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 10 | 0.090 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 40 | 0.080 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 2 | 0.080 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 10 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 171 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 121 | 0.070 |
Why?
|
| Alemtuzumab | 1 | 2008 | 3 | 0.070 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 3 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 35 | 0.070 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 3 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 42 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2007 | 14 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 642 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 84 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 3874 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 29 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2007 | 29 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 83 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 111 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2018 | 402 | 0.060 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.060 |
Why?
|
| Complement C4b | 1 | 2006 | 1 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2006 | 59 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1528 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 907 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 25 | 0.050 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 5 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2024 | 23 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2018 | 22 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 25 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 82 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1264 | 0.040 |
Why?
|
| Benzofurans | 1 | 2021 | 5 | 0.040 |
Why?
|
| Naphthoquinones | 1 | 2021 | 7 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2021 | 30 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 21 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2021 | 45 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 60 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 30 | 0.040 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 142 | 0.040 |
Why?
|
| United States | 2 | 2018 | 1814 | 0.040 |
Why?
|
| Mitotane | 1 | 2019 | 4 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 109 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 13 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 295 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 21 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 15 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 52 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 7 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 13 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 102 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2019 | 82 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 240 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1045 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 265 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 41 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2017 | 33 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 23 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 130 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 23 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 101 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 78 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 167 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 656 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 202 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 340 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 5 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 7 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 59 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 13 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 72 | 0.030 |
Why?
|
| Sarcoma | 1 | 2017 | 140 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 280 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 232 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 445 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 376 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 540 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 507 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 19 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2011 | 15 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 66 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 56 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 310 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 12 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 13 | 0.020 |
Why?
|
| Child | 1 | 2012 | 1164 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 2 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 20 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 198 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 3 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2006 | 6 | 0.010 |
Why?
|
| Atrophy | 1 | 2006 | 68 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 38 | 0.010 |
Why?
|